Semaglutide
10 mg8% purityLot #SEMAGL-2026-001
SKU of selected dimension: PEP-SEMA-10MG
Semaglutide is a synthetic agonist of the GLP-1 (Glucagon-Like Peptide-1) receptor that shares approximately 94% structural similarity with endogenous human GLP-1. Initially designed as a therapeutic option for type 2 diabetes, it has since become one of the most extensively studied compounds in metabolic science. By replicating the activity of the natural incretin hormone GLP-1, Semaglutide activates GLP-1 receptors located throughout the pancreas, central nervous system, and gastrointestinal tract. This receptor stimulation promotes glucose-dependent insulin secretion, reduces glucagon output, slows the rate of gastric emptying, and influences hypothalamic pathways involved in appetite regulation, leading to lower caloric intake. Findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program reported average body weight reductions ranging from 14.9% to 17.4% over a 68-week period. Additional studies published in the New England Journal of Medicine have demonstrated meaningful cardiovascular benefits, including a reduced incidence of major adverse cardiovascular events.
€230.58incl. VAT
✅ In Stock (40)
Volume pricing
| Quantity | Unit price | Savings |
|---|---|---|
| 1 vial | 230.58 € | — |
| 3 vials (−7%) | 214.72 € | −7% |
| 5 vials (−12%) | 202.52 € | −12% |
Ratings & reviews
Log in to rate this product after your order arrives. login
Certificate of Analysis
Lab Verified✓View certificate before purchase — transparency guaranteed
Research Profile
Semaglutide — scientific profile
Content is for educational and research purposes. Research Use Only.
- Semaglutide is a synthetic agonist of the GLP-1 (Glucagon-Like Peptide-1) receptor that shares approximately 94% structural similarity with endogenous human GLP-1. Initially designed as a therapeutic option for type 2 diabetes, it has since become one of the most extensively studied compounds in metabolic science. By replicating the activity of the natural incretin hormone GLP-1, Semaglutide activates GLP-1 receptors located throughout the pancreas, central nervous system, and gastrointestinal tract. This receptor stimulation promotes glucose-dependent insulin secretion, reduces glucagon output, slows the rate of gastric emptying, and influences hypothalamic pathways involved in appetite regulation, leading to lower caloric intake. Findings from the STEP (Semaglutide Treatment Effect in People with Obesity) clinical program reported average body weight reductions ranging from 14.9% to 17.4% over a 68-week period. Additional studies published in the New England Journal of Medicine have demonstrated meaningful cardiovascular benefits, including a reduced incidence of major adverse cardiovascular events.
%22%20stroke-width%3D%223%22%2F%3E%3Ccircle%20cx%3D%2278%22%20cy%3D%2292%22%20r%3D%228%22%20fill%3D%22var(--pep-gray-light)%22%2F%3E%3Cpath%20d%3D%22M55%20125%20L95%2095%20L125%20115%20L145%2090%22%20fill%3D%22none%22%20stroke%3D%22var(--pep-gray-light)%22%20stroke-width%3D%223%22%20stroke-linecap%3D%22round%22%20stroke-linejoin%3D%22round%22%2F%3E%3C%2Fsvg%3E)